ADMA - NASDAQ

ADMA Biologics, Inc.

ADMA Biologics, Inc.

ADMAยทNASDAQ

$7.76

-1.8%
HealthcareBiotechnology

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$1.80B
EPS0.6200
P/E Ratio12.52
Earnings Date08/05/2026
ADMA Biologics, Inc.

ADMA Biologics, Inc. Fair Value Envelope

ADMA ยท NASDAQ

Our analysis suggests that ADMA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.76, this represents a potential HIDDEN relative to our calculated worth for ADMA Biologics, Inc..

HIDDEN
Intrinsic Value
Current Price: $7.76

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value$39.9M
+ Cash & Equivalents$87.6M
Firm Value$127.5M
- Debt$79.9M
Equity Value$47.6M
/ Shares Outstanding237,997,765B
DCF Value$0
OVERVALUED BY 97%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
$25.2M
$12.6M
$6.3M
$3.1M
$1.6M
$787.4K
$393.7K
$196.9K
$98.4K
$49.2K
Maintenance CapEx
-$2.3M
-$1.1M
-$564.4K
-$282.2K
-$141.1K
-$70.5K
-$35.3K
-$17.6K
-$8.8K
-$4.4K
Owner Earnings
$22.9M
$11.5M
$5.7M
$2.9M
$1.4M
$716.9K
$358.4K
$179.2K
$89.6K
$44.8K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
$21.2M
$9.8M
$4.6M
$2.1M
$975.8K
$451.8K
$209.1K
$96.8K
$44.8K
$20.8K
Terminal Value represents 0.9% of Enterprise Value

Related Guides

Blog Categories

Continue your ADMA research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.